Skip to main content

Table 1 Clinical characteristics of the TSC Cohort

From: The TAND checklist: a useful screening tool in children with tuberous sclerosis and neurofibromatosis type 1

  TSC patients
(n = 42)
Mean age (years) ± SD 11.36 ± 4.19  
Range 4–19  
  n (&)
Gender
 Male 19 (45.2%)
 Female 23 (54.8%)
Diagnostic criteria met for TSC 42 (100%)
Tubers (brain MRI) 37 (88.1%)
Never had epilepsy 13 (31.0%)
Well controlled epilepsy (seizure free) 16 (38.0%)
Active epilepsy 13 (31.0%)
 One or more seizures/day 3 (23.1%)
 One or more seizures/week 8 (61.5%)
Sporadic seizures 2 (15.4%)
Seizure types
 Infantile Spasms 4 (13.8%)
 Focal seizures 19 (65.5%)
 Infantile Spasms + Focal seizures 2 (6.9%)
 Generalized seizures 4 (13.8%)
 Antiepileptic treatment 28 (66.7%)
 Monotherapy 11 (39.3%)
 Polytherapy 17 (60.7%)
Neurosurgical treatment for epilepsy 3 (7.1%)
Subependymal giant cell astrocytoma (SEGA) 10 (23.8%)
 Neurosurgical treatment for SEGA 2 (20.0%)
 SEGA treated with Everolimus 6 (60.0%)
 Stable SEGA on brain MRI 2 (20.0%)
Received IQ assessment 42 (100%)
Median IQ ± SD 74.48 ± 28.05  
Range 20–134  
 Normal IQ 17 (40.5%)
 BIF 10 (23.8%)
 Mild ID 4 (9.5%)
 Moderate ID 8 (19.0%)
 Severe/profound ID 3 (7.1%)
Received formal psychiatric assessment 12 (28.6%)
 ASD 4 (33.3%)
 ADHD 6 (50.0%)
 Anxious/Depressed Disorder 2 (16.6%)
Additional support in school (i.e. IEP) 28 (66.7%)
SLD 5 (11.9%)
Low self-esteem (per parents’ report) 11 (26.2%)
Very high levels of stress in families 16 (38.1%)
Very high levels of stress between parents 18 (42.9%)